New class of KRAS inhibitors shows promise in shrinking NF1 nerve tumors

A scientist at Cincinnati Children's who has hunted for decades for ways to shrink the painful and disfiguring nerve tumors caused by neurofibromatosis type 1 (NF1) has made a new breakthrough in the quest. Nancy Ratner, Ph.D., and a team of nine co-authors are reporting that a novel class of medications—known as KRAS inhibitors—shows at least as much potential as FDA-approved MEK inhibitors in shrinking NF1 tumors.

≈